Mechanism of tDCS-induced Learning Enhancement

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess whether the application of a selective serotonin reuptake inhibitor (SSRI) enhances and prolongs the learning enhancement achieved by anodal transcranial direct current stimulation (atDCS). For this, young and older healthy subjects will be tested with a well established learning paradigm. Results of this study may help to support the application of atDCS also in patients, e.g. with dementia or mild cognitive impairment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of tDCS-enhanced Cognitive Control Training on Depression

NCT03518749

Depression Unipolar

UNKNOWN NA

Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients

NCT03039387

Anodal Stimulation tDCS Major Depression Cognitive Control +1 more

UNKNOWN NA

Boosting Psychotherapy Effects by Means of Transcranial Direct Current Stimulation

NCT05866042

Major Depressive Disorder

COMPLETED NA

Long-term Effect of tDCS in Patients With Disorders of Consciousness

NCT03114397

Disorder of Consciousness

COMPLETED NA

Methods to Enhance Transcranial Direct Stimulation (tDCS)

NCT01135953

Healthy Volunteers Brain Excitation

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Young and Older Adults

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

tDCS + SSRI

Group Type EXPERIMENTAL

tDCS

Intervention Type PROCEDURE

Citalopram

Intervention Type DRUG

tDCS + placebo

Group Type PLACEBO_COMPARATOR

tDCS

Intervention Type PROCEDURE

sham-tDCS + SSRI

Group Type SHAM_COMPARATOR

Citalopram

Intervention Type DRUG

sham-DCS + placebo

Group Type PLACEBO_COMPARATOR

sham-tDCS + placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tDCS

Intervention Type PROCEDURE

Citalopram

Intervention Type DRUG

sham-tDCS + placebo

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

transcranial direct current stimulation SSRI

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* right handedness
* unobtrusive neuropsychological screening
* ability to provide written informed consent
* no pathological findings in head MRI
* age: 18 to 35 years (young adults) or 50-80 years (older adults)
* Highly effective contraception (Pearl Index \< 1) or reliable abstinence from any heterosexual relationships in women of childbearing potential

Exclusion Criteria

* severe internal or psychiatric disease (especially depression or suicidal thoughts)
* epilepsy
* cognitive impairment (\< SD under age adjusted norm in neuropsychological testing)
* concurrent taking of serotonin precursors (tryptophan, 5-HTP) or MAO inhibitors
* concurrent taking of tramadol or triptans
* concurrent taking of pimozide or linezolid
* concurrent taking of other drugs prolonging the QT-interval
* long-QT-syndrome
* hypokalemia or hypomagnesemia
* known intolerance of the study medication
* pregnancy or lactation
* participation in another drug-interventional clinical trial within the last month or during the entire study
* probands that are placed in an institution due to official or judicial order
* non-agreement to save and transmit pseudonymised study data within the clinical trial

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes